Novo Nordisk’s Wegovy Wins a Strategic NHS Breakthrough

The NICE recommendation marks a notable policy shift. Reuters reported that it is the first time a GLP-1 drug has been endorsed in the UK for this use, and NICE said eligible patients include adults with a body mass index of at least 27 who have previously had a heart attack, stroke, or serious circulation problems in the legs. NICE also emphasized that semaglutide would not be prescribed automatically; instead, a GP or specialist would decide whether it is appropriate for each patient. That framing is important because it positions Wegovy not as a mass-market wellness product, but as part of a targeted, clinically supervised cardiovascular treatment pathway.

The clinical evidence behind the decision is what gives the story real weight. NICE said the recommendation was supported by the SELECT trial, in which 17,604 patients receiving semaglutide alongside standard cardiovascular medicines were 20% less likely to suffer a serious cardiovascular event than patients on placebo plus standard care. Just as importantly, NICE said the benefit appeared early, before major weight loss had occurred, suggesting semaglutide may have direct cardiovascular effects rather than working only through lower body weight. That changes the commercial and medical narrative around Wegovy, because it broadens the drug’s value proposition from weight management to event prevention.

For Novo Nordisk, the timing of the endorsement is especially meaningful. Reuters noted that Wegovy had already received UK regulatory approval in 2024 for reducing major cardiovascular events in this patient group, but access for that use had largely been limited to people paying privately. Moving into NHS-backed care gives the drug far stronger institutional legitimacy and could support steadier long-term demand. It also helps Novo defend its franchise while the broader GLP-1 market becomes more competitive: Reuters reported in February that the company had warned of “unprecedented” pricing pressure, and on March 31 it reported further price cuts for Ozempic and Wegovy in India after semaglutide’s patent expired there.

The market appears to be treating the NICE decision as incrementally positive. By early April 1 trading, Novo Nordisk’s U.S.-listed shares were at $36.75, up about 4.11% from the previous close. That does not erase the bigger strategic questions facing the company, especially around competition from Eli Lilly and pressure on pricing, but it does show why investors still care about payer-backed wins. The NHS endorsement signals that semaglutide’s cardiovascular benefits are not just clinically compelling but economically credible enough for a major public health system to adopt. In a market increasingly defined by reimbursement battles as much as by scientific results, that is a valuable form of validation for Novo Nordisk.